{"analyses":[{"ciLowerLimit":"1.34","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"3.52","estimateComment":"The odds ratio and 95% confidence interval (CI) were calculated using a stratified Cochran-Mantel-Haenszel test.","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.0011","pValueComment":"The one-sided p-value was calculated using a stratified Cochran-Mantel-Haenszel test.","paramType":"Odds Ratio (OR)","paramValue":"2.17","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"69.1","upperLimit":"82.6","value":"76.4"},{"groupId":"OG001","lowerLimit":"52.4","upperLimit":"67.9","value":"60.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"164"}],"units":"Participants"}],"description":"BOR was defined as the percentage of participants who achieved an overall response (CR+PR) based on cGvHD disease assessments (National Institutes of Health Consensus Criteria) without the requirement of additional systemic therapies for an earlier progression, mixed response, or non-response at any time point (up to Cycle 7 Day 1 or the start of additional systemic therapy for cGvHD). Scoring of response was relative to the organ score at the time of randomization. CR: complete resolution of all signs and symptoms of cGVHD in all evaluable organs without the initiation or addition of new systemic therapy. PR: improvement in at least one organ (e.g., improvement of 1 or more points on a 4- to 7-point scale, or an improvement of 2 or more points on a 10- to 12-point scale) without progression in other organs or sites, initiation, or addition of new systemic therapies. This analysis was based on the primary cutoff date (May 2020).","dispersionType":"95% Confidence Interval","groups":[{"description":"Ruxolitinib was administered orally twice per day at a dose of 10 milligrams (mg).","id":"OG000","title":"Ruxolitinib"},{"description":"Participants received best available therapies (BATs), including, but not limited to, extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), infliximab, rituximab, pentostatin, imatinib, and ibrutinib based on the investigator's decision.","id":"OG001","title":"Best Available Therapy"}],"paramType":"NUMBER","populationDescription":"FAS. Data reported are from the start of the study to Cycle 7 Day 1 (data cutoff of 08 May 2020).","reportingStatus":"POSTED","timeFrame":"up to Cycle 7 Day 1 (each cycle was comprised of 4 weeks)","title":"Best Overall Response (BOR) at Cycle 7 Day 1","type":"SECONDARY","unitOfMeasure":"percentage of participants"}